Case Study
Billion-Dollar Life
Science Company
The Challenge
Our Role
Key Activities
The Impact
A global life science company came to us with a common but critical challenge: their existing lateral flow assay worked well operationally but lacked the sensitivity required for reliable detection at lower target levels.
They were seeking a rapid, quantitative test for a small protein with sensitivity in the ng/mL range, the ability to measure a 5-fold concentration range, and results delivered in under 10 minutes. The team needed a solution that maintained the ease of use and speed of an LFA, but delivered improved analytical performance without requiring a full shift to a lab-based platform. They partnered with BurstDX to leverage our expertise in rapid small-molecule quantification.
BurstDX was selected as a partner based on our platform’s ability to replicate ELISA-level performance in a compact, fully automated device. Our team worked closely with theirs to translate their existing assay protocol into a custom solution on CaDI, our chemiluminescent diagnostic platform.
Integrated enzyme-based signal amplification to enhance assay performance
Maintained a familiar rapid test workflow with results delivered in under 10 minutes
Developed and delivered a functional assay within six weeks
Demonstrated improved sensitivity and expanded working range without increasing cost
Facilitated bi-monthly progress updates to ensure alignment with partner needs.
BurstDX met and exceeded the outlined deliverables within 6 weeks.
This project demonstrated how CaDI can be used to extend or upgrade existing rapid lateral flow assays, creating opportunities for broader use cases and higher-confidence results at the point-of-need.
The success of this partnership has opened the door to further development across new targets and sample types.
